Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
232 SEK | -0.85% | +2.88% | +9.43% |
Feb. 07 | Transcript : CellaVision AB, Q4 2023 Earnings Call, Feb 07, 2024 | |
Feb. 07 | CellaVision AB Proposes Dividend for the Year 2023 | CI |
Sales 2023 | 677M 64.89M | Sales 2024 * | 782M 74.91M | Capitalization | 5.53B 530M |
---|---|---|---|---|---|
Net income 2023 | 130M 12.46M | Net income 2024 * | 178M 17.05M | EV / Sales 2023 | 7.38 x |
Net cash position 2023 | 56.94M 5.46M | Net cash position 2024 * | 117M 11.2M | EV / Sales 2024 * | 6.93 x |
P/E ratio 2023 |
38.8
x | P/E ratio 2024 * |
31.5
x | Employees | - |
Yield 2023 |
1.06% | Yield 2024 * |
1.07% | Free-Float | 61.96% |
Latest transcript on CellaVision AB
1 day | -0.85% | ||
1 week | +2.88% | ||
Current month | -5.69% | ||
1 month | -13.59% | ||
3 months | +16.35% | ||
6 months | +30.78% | ||
Current year | +9.43% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 94-11-15 | |
Simon Ostergaard
CEO | Chief Executive Officer | 53 | 21-03-20 |
Magnus Blixt
DFI | Director of Finance/CFO | 58 | 13-05-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 94-11-15 | |
Lotta Jarleryd
BRD | Director/Board Member | 58 | 22-05-10 |
Mikael Worning
CHM | Chairman | 62 | 20-04-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 232 | -0.85% | 21,652 |
24-03-15 | 234 | +0.86% | 206,954 |
24-03-14 | 232 | -0.64% | 11,077 |
24-03-13 | 233.5 | -2.30% | 8,095 |
24-03-12 | 239 | +4.82% | 31,537 |
Delayed Quote Nasdaq Stockholm, March 18, 2024 at 12:29 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.43% | 539M | |
+6.87% | 24.09B | |
-33.51% | 3.24B | |
+30.31% | 1.9B | |
+11.50% | 1.74B | |
+31.11% | 1.37B | |
+4.14% | 1.21B | |
-12.51% | 994M | |
-16.54% | 711M | |
-.--% | 312M |